445 related articles for article (PubMed ID: 20697068)
1. Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
[TBL] [Abstract][Full Text] [Related]
2. Is it time to ReSET the standard for estrogen receptor testing in breast cancer?
Oesterreich S; Lee AV; Davidson NE
J Clin Oncol; 2010 Sep; 28(27):4101-3. PubMed ID: 20697070
[No Abstract] [Full Text] [Related]
3. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Bianchini G; Pusztai L; Karn T; Iwamoto T; Rody A; Kelly C; Müller V; Schmidt S; Qi Y; Holtrich U; Becker S; Santarpia L; Fasolo A; Del Conte G; Zambetti M; Sotiriou C; Haibe-Kains B; Symmans WF; Gianni L
Breast Cancer Res; 2013; 15(5):R86. PubMed ID: 24060333
[TBL] [Abstract][Full Text] [Related]
4. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
5. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
[TBL] [Abstract][Full Text] [Related]
8. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
Prat A; Parker JS; Fan C; Cheang MCU; Miller LD; Bergh J; Chia SKL; Bernard PS; Nielsen TO; Ellis MJ; Carey LA; Perou CM
Ann Oncol; 2012 Nov; 23(11):2866-2873. PubMed ID: 22532584
[TBL] [Abstract][Full Text] [Related]
9. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
10. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Sparano JA; Gray RJ; Ravdin PM; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
N Engl J Med; 2019 Jun; 380(25):2395-2405. PubMed ID: 31157962
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
[TBL] [Abstract][Full Text] [Related]
13. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
14. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
15. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
18. A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
Kerr DA; Wittliff JL
Horm Cancer; 2011 Oct; 2(5):261-71. PubMed ID: 21826535
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Albain KS; Barlow WE; Shak S; Hortobagyi GN; Livingston RB; Yeh IT; Ravdin P; Bugarini R; Baehner FL; Davidson NE; Sledge GW; Winer EP; Hudis C; Ingle JN; Perez EA; Pritchard KI; Shepherd L; Gralow JR; Yoshizawa C; Allred DC; Osborne CK; Hayes DF;
Lancet Oncol; 2010 Jan; 11(1):55-65. PubMed ID: 20005174
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
